NCT06735807Completed
Generated AI-informed Intervention (Emohaa) vs Group ACT vs WL on Emotional Distress
Comparing Generated AI (Emohaa) and Group ACT in Reducing Emotional Distress: a Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 25 Apr 2025
Brief summary (registry, in English)
Emotional Distress, such as anxiety and depression, is an essential issue worldwide. There have been several evidence-based psychotherapies that are effective in improving emotional distress, such as Acceptance and Commitment Therapy (ACT). However, the scarcity of professionals and the imbalance in the distribution of mental health resources prevent individuals in need from accessing immediate and effective help. Artificial intelligence (AI) has the potential to promote this problem. The existing studies have provided preliminary support for the application of AI in mental health interventions. One such model, Emohaa, a generated AI model, has been examined for its effectiveness in adult emotional distress. However, despite the limited reliability of the single-group design, parallel randomized controlled trials are scarce to validate this finding further. This present study is to fill this gap. This study aims to examine the effectiveness of the generated AI (Emohaa) in reducing emotional distress, including anxiety and depression, compared with group ACT and waitlist. In this parallel randomized controlled trial, it is hypothesized that (1) Compared with the waitlist, Emohaa and group ACT could significantly improve participants' emotional distress, including anxiety and depression symptoms; (2) Emohaa would lead to a greater reduction in anxiety and depression symptoms compared with group ACT.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 6 Dec 2024
- Start date
- Sept 2024
- Primary completion date
- Dec 2024
- Lead sponsor
- Central University of Finance and Economics, China
- Diseases
- Depression
- NCT number
- NCT06735807
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From Sept 2024 to the primary completion date, Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Received other psychological or pharmacological interventions in the last month
Other illness
- Other mental or physical illnesses requiring urgent medical assistance;
Other
- High risk of self-injury and suicide;
- Presence of psychotic symptoms (i.e., delusions);
- Serious substance use problems;
Who the study is looking for
- Adults with 18-25 ages;
- Suffering from emotional distress (PHQ-9 \> 9 or GAD-7 \> 9);
- Ability to use the mobile phone to interact with AI;
- Consent to participate in the study.
Age in the registry: 18 years to 25 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Central University of Finance and Economics, China Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.